CA2418383A1 - Radiolabelled metal transport proteins as imaging agents - Google Patents
Radiolabelled metal transport proteins as imaging agents Download PDFInfo
- Publication number
- CA2418383A1 CA2418383A1 CA002418383A CA2418383A CA2418383A1 CA 2418383 A1 CA2418383 A1 CA 2418383A1 CA 002418383 A CA002418383 A CA 002418383A CA 2418383 A CA2418383 A CA 2418383A CA 2418383 A1 CA2418383 A1 CA 2418383A1
- Authority
- CA
- Canada
- Prior art keywords
- lactoferrin
- product according
- 99mtc
- tumour
- labelled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 60
- 239000002184 metal Substances 0.000 title claims abstract description 60
- 102000014914 Carrier Proteins Human genes 0.000 title claims abstract description 47
- 108010078791 Carrier Proteins Proteins 0.000 title claims abstract description 47
- 239000012216 imaging agent Substances 0.000 title claims description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 53
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 35
- 229910052742 iron Inorganic materials 0.000 claims abstract description 21
- 238000003384 imaging method Methods 0.000 claims abstract description 16
- 108010063045 Lactoferrin Proteins 0.000 claims description 37
- 229940078795 lactoferrin Drugs 0.000 claims description 36
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 35
- 235000021242 lactoferrin Nutrition 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 23
- 239000003638 chemical reducing agent Substances 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 239000007951 isotonicity adjuster Substances 0.000 claims description 7
- 238000002372 labelling Methods 0.000 claims description 7
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical group OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 6
- 239000012736 aqueous medium Substances 0.000 claims description 6
- 239000013011 aqueous formulation Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000011835 investigation Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 229960005219 gentisic acid Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical class [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 claims description 2
- 102100032241 Lactotransferrin Human genes 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000012581 transferrin Substances 0.000 description 44
- 102000004338 Transferrin Human genes 0.000 description 43
- 108090000901 Transferrin Proteins 0.000 description 43
- 239000000243 solution Substances 0.000 description 43
- 230000027455 binding Effects 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 21
- 229910052702 rhenium Inorganic materials 0.000 description 21
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 21
- 102000010445 Lactoferrin Human genes 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 15
- 238000001228 spectrum Methods 0.000 description 14
- 229910052713 technetium Inorganic materials 0.000 description 13
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 13
- 108010054176 apotransferrin Proteins 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000002070 Transferrins Human genes 0.000 description 7
- 108010015865 Transferrins Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000004448 titration Methods 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 108010038047 apolactoferrin Proteins 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 108010083590 Apoproteins Proteins 0.000 description 2
- 102000006410 Apoproteins Human genes 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108010026206 Conalbumin Proteins 0.000 description 2
- -1 Fe3+ ions Chemical class 0.000 description 2
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 2
- 101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 2
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 2
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 229910052733 gallium Inorganic materials 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229910052779 Neodymium Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLJSYHOPCNWUNE-IEOVAKBOSA-N [99Tc].CC1=CC(C)=C(NC(=O)CN(CC(O)=O)CC(O)=O)C(C)=C1Br Chemical compound [99Tc].CC1=CC(C)=C(NC(=O)CN(CC(O)=O)CC(O)=O)C(C)=C1Br JLJSYHOPCNWUNE-IEOVAKBOSA-N 0.000 description 1
- DMVSPCYHPLCMJR-UHFFFAOYSA-N [Re].[Sc] Chemical compound [Re].[Sc] DMVSPCYHPLCMJR-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(III) nitrate Inorganic materials [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004890 malting Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 230000008866 synergistic binding Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-M tyrosinate group Chemical group N[C@@H](CC1=CC=C(C=C1)O)C(=O)[O-] OUYCCCASQSFEME-QMMMGPOBSA-M 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0019412.6A GB0019412D0 (en) | 2000-08-08 | 2000-08-08 | New imaging agent |
| GB0019412.6 | 2000-08-08 | ||
| PCT/GB2001/003531 WO2002011772A2 (en) | 2000-08-08 | 2001-08-07 | Radiolabelled metal transport proteins as imaging agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2418383A1 true CA2418383A1 (en) | 2002-02-14 |
Family
ID=9897174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002418383A Abandoned CA2418383A1 (en) | 2000-08-08 | 2001-08-07 | Radiolabelled metal transport proteins as imaging agents |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7160536B2 (enExample) |
| EP (1) | EP1307240A2 (enExample) |
| JP (1) | JP2004505932A (enExample) |
| AU (1) | AU2001278585A1 (enExample) |
| CA (1) | CA2418383A1 (enExample) |
| GB (1) | GB0019412D0 (enExample) |
| WO (1) | WO2002011772A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0019412D0 (en) * | 2000-08-08 | 2000-09-27 | Univ York | New imaging agent |
| US20060083684A1 (en) * | 2002-02-12 | 2006-04-20 | Walton Paul H | Method of radio-labelling biomolecules |
| US7183381B2 (en) | 2004-10-26 | 2007-02-27 | Agennix, Inc. | Composition of lactoferrin related peptides and uses thereof |
| DE102005051366A1 (de) * | 2005-10-25 | 2007-04-26 | Degussa Gmbh | Drug Delivery Systeme |
| CA2627459C (en) * | 2005-10-25 | 2011-08-09 | Evonik Degussa Gmbh | Preparations containing hyperbranched polymers |
| EP1982698A1 (de) * | 2007-04-18 | 2008-10-22 | Evonik Degussa GmbH | Präparate zur gesteuerten Freisetzung von bioaktiven Naturstoffen |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4057617A (en) * | 1975-05-15 | 1977-11-08 | Abramovici J | Method of labeling proteins with technetium |
| JPH08505119A (ja) | 1992-07-06 | 1996-06-04 | バイオミラ、インコーポレーテッド | 接合目的のためのタンパク質の光活性化 |
| GB0019412D0 (en) * | 2000-08-08 | 2000-09-27 | Univ York | New imaging agent |
-
2000
- 2000-08-08 GB GBGB0019412.6A patent/GB0019412D0/en not_active Ceased
-
2001
- 2001-08-07 CA CA002418383A patent/CA2418383A1/en not_active Abandoned
- 2001-08-07 US US10/344,079 patent/US7160536B2/en not_active Expired - Fee Related
- 2001-08-07 EP EP01956661A patent/EP1307240A2/en not_active Withdrawn
- 2001-08-07 WO PCT/GB2001/003531 patent/WO2002011772A2/en not_active Ceased
- 2001-08-07 AU AU2001278585A patent/AU2001278585A1/en not_active Abandoned
- 2001-08-07 JP JP2002517105A patent/JP2004505932A/ja active Pending
-
2006
- 2006-10-05 US US11/543,671 patent/US20070036720A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7160536B2 (en) | 2007-01-09 |
| WO2002011772A3 (en) | 2002-04-25 |
| US20070036720A1 (en) | 2007-02-15 |
| EP1307240A2 (en) | 2003-05-07 |
| AU2001278585A1 (en) | 2002-02-18 |
| US20040013675A1 (en) | 2004-01-22 |
| GB0019412D0 (en) | 2000-09-27 |
| WO2002011772A2 (en) | 2002-02-14 |
| JP2004505932A (ja) | 2004-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sarko et al. | Bifunctional chelators in the design and application of radiopharmaceuticals for oncological diseases | |
| Rao et al. | Technetium (V) and rhenium (V) complexes of 2, 3-bis (mercaptoacetamido) propanoate. Chelate ring stereochemistry and influence on chemical and biological properties | |
| Maecke et al. | 68Ga-PET radiopharmacy: a generator-based alternative to 18F-radiopharmacy | |
| JPS62270600A (ja) | キヤリヤ−分子の金属イオン標識化 | |
| JPH02504387A (ja) | 金属イオンで抗体を標識付けする方法 | |
| CZ20032597A3 (cs) | Analogy kyseliny askorbové pro metaloradiofarmaceutika | |
| KR20050119205A (ko) | 갈륨-68을 얻는 방법, 갈륨-68의 용도 및 상기 방법의수행을 위한 장치 | |
| Liu et al. | Labeling biomolecules with radiorhenium-A review of the bifunctional chelators | |
| JPH07110869B2 (ja) | 放射性医薬品として使用できる９９ｍＴｃ、１８６Ｒｅまたは１８８Ｒｅの窒化物錯体の製造方法 | |
| JPS58126817A (ja) | 放射性核種標識タンパク質、とくに抗体または抗体断片の製造法 | |
| EP0719790B1 (en) | Metal chelate forming peptides and use thereof | |
| Frindel et al. | Cyclam te1pa for 64 Cu PET imaging. Bioconjugation to antibody, radiolabeling and preclinical application in xenografted colorectal cancer | |
| JPH06508357A (ja) | 標識ポリペプチド、その製造法および使用 | |
| Ruser et al. | Synthesis and evaluation of two new bifunctional carboxymethylated tetraazamacrocyclic chelating agents for protein labeling with indium-111 | |
| CA2418383A1 (en) | Radiolabelled metal transport proteins as imaging agents | |
| Marquez-Nostra et al. | The radiopharmaceutical chemistry of zirconium-89 | |
| JP7744240B2 (ja) | キレート化ａａｚｔａコンジュゲートおよびその錯体 | |
| EP3452436A2 (en) | In-kit preparation of gallium-68 labelled radiopharmaceuticals | |
| Huynh et al. | Direct radiofluorination of a heat-sensitive antibody by Al–18 F complexation | |
| Verbeke et al. | Technetium-99m mercaptoalbumin as a potential substitute for technetium-99m labelled red blood cells | |
| Jalilian et al. | [201Tl](III)-bleomycin for tumor imaging | |
| US5827498A (en) | Tumor affinity peptide, and radioactive diagnostic agent and radioactive therapeutic agent containing the peptide | |
| Kowalsky | Technetium radiopharmaceutical chemistry | |
| Maruk et al. | Novel 99 m Tc radiopharmaceuticals with bifunctional chelating agents | |
| Vallabhajosula | Metal Radionuclides for Molecular Imaging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |